4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Presbyopia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Presbyopia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 14 ongoing clinical trials involving Presbyopia
Of the 14 trials,4 trials are in Phase III
Furthermore, 3 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Presbyopia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Presbyopia, an ophthalmology indication. The highest number of ongoing clinical trials involving Presbyopia is conducted in North America. Asia-pacific is another prominent region involved in Presbyopia-related drug trials.

Intratus Inc: The leading ongoing Presbyopia related clinical trial sponsor

Intratus Incis the top sponsor for Presbyopia-related ongoing clinical trial.

Allergan Ltd, Orasis Pharmaceuticals Ltd, and Optall Vision are a few other notable sponsors involving Presbyopia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Presbyopia

Neostigmine methylsulfate(Mypilin), and Pilocarpine hydrochloride (Vuity)are among the key marketed drugs involving Presbyopia.     

Neostigmine methylsulfate is a carbamic acid derivative acts as parasympathomimetic agent. It is formulated as solution for ophthalmic route of administration. It functions via Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Inhibitor mechanism of action. Neostigmine methylsulfate is indicated for the treatment of Presbyopia. Mypilin is sold in Japan by Nitten Pharmaceutical Co Ltd.

Pilocarpine hydrochloride (Vuity) is a cholinergic parasympathomimetic agent and an ophthalmological agent. It is formulated as solution, drops for ophthalmic route of administration. It functions via Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Agonist mechanism of action. Vuity is indicated for the treatment of presbyopia in adults. Vuity was approved in 2021 and is marketed in the US by Allergan USA Inc.

Explore the latest trends and actionable insights on the Presbyopia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Presbyopia Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store